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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common monogenic diseases with 
an estimated point prevalence of 1 in 2500 and a genetic prevalence of 1 in 10001,2. It is the fourth most common 
cause of end-stage renal disease (ESRD) afecting 10–12 million people world-wide. In ADPKD, the diseased kid-
neys contain numerous luid-illed cysts which grow to destroy normal kidney tissue. he major risk factors for 
worse kidney outcome include genotype, age, gender and total kidney volume (reviewed in1). he vast majority of 
patients with ADPKD carry germline mutations in PKD1 or PKD2. Regarding ESRD, a clear genotype-phenotype 
correlation has been demonstrated, patients with PKD1 truncating mutations reaching ESRD earlier than those 
with PKD2 mutations and those with PKD1 non-truncating mutations having an intermediate phenotype3,4. Total 
kidney volume (TKV) adjusted for age and height is also a strong predictor of renal prognosis5. Finally, it has been 
observed that male patients typically reach ESRD earlier than females and have larger kidneys3,6.
To date, only one drug (tolvaptan) has been approved to treat ADPKD patients with a high risk of disease pro-
gression7. However, it is only moderately efective and is associated with a high incidence of poorly-tolerated side 
efects mainly due to increased aquaresis8. Monthly monitoring of liver function is also mandated in all countries 
where tolvaptan has been licenced due to idiosyncratic liver toxicity in the pivotal trials.
he ADPKD proteins PC1 (polycystin-1) and PC2 (polycystin-2) are thought to form a plasma membrane 
receptor-ion channel complex9,10. he exact functions of the PC1-PC2 complex remain unclear, although muta-
tions in either lead to altered Ca2+ and cAMP signalling11. Nonetheless, changes in a range of other signalling 
pathways and cellular functions have been reported12. PC2 has been localised in multiple cellular compartments 
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including primary cilia, apical and basolateral membranes, endosomes, mitochondria and the endoplasmic retic-
ulum where it could mediate PC1-independent functions in intracellular Ca2+ regulation10,13–15.
he high degree of sequence conservation between zebraish pkd2 and human PKD2 (67% identity) has stim-
ulated several groups to use zebraish pkd2 morphants as a model to study ADPKD16–18. A striking characteristic 
feature of all reported pkd2 morphants and mutants is a profound upward tail curvature at 40 hpf (hence the fur-
ther denomination of the pkd2 mutant as curly up (cup) from when it was irst isolated from a phenotype-based 
screen19). his contrasts with zebraish ‘cilia’ mutants where conversely there is downward tail curvature19–21. 
Unlike pkd2 mutants, pkd2 morphants develop cystic kidneys, although this appears to be restricted to the glo-
merulus and proximal tubules rather than the entire pronephros like in other cystic cilia mutants16,17,22. Obara et 
al. suggested that a partial cloacal occlusion in pkd2 could lead to glomerular dilatation secondary to a build-up 
of luid16.
he utility and advantages of using zebraish embryos as a model for in vivo chemical library screening has 
been exploited by many groups for non-renal diseases23,24 although a large unbiased chemical screen for ADPKD 
has not been previously reported. he potential for such an approach however has been shown by a previous 
study using a small focussed library in pkd2 mutants25. Here, an inhibitor of histone deacetylase (HDAC) iden-
tiied from their screen was subsequently also tested in several Pkd1 mouse models and found to inhibit disease 
progression26,27. In this paper, we report the results of a high throughput chemical library screen in pkd2 mutant 
zebraish using tail curvature as a phenotypic readout. Combined with validation assays in mammalian cyst 
assays, this approach allowed us to identify two new pathways of potential relevance for future drug development 
i.e. ALK5 (Transforming growth factor beta receptor I) and non-canonical androgen signalling.

ƤǤ he strategy 
we adopted is shown schematically in Fig. 1. We initially explored the possibility of using morpholino-induced 
pkd2 knockdown, to utilise both glomerular dilation and tail curvature as independent readouts for a chemical 
library screen in zebraish embryos, as has been previously reported25. However, in our hands, morpholino injec-
tions were associated with low and variable penetrant cyst formation as well as highly variable tail curvature. 
Successful high-throughput screens require robust and fully penetrant efects, especially where the aim is to iden-
tify phenotype suppressors. We therefore decided to use a TILLING ENU zebraish mutant generated previously 
i.e. pkd2hu2173/hu2173 (henceforth referred to as pkd2−/−) using tail curvature (curly-up) as a quantitative readout 
(Fig. 1b), as previously reported in a small-scale screen25. Dechorionated mutant embryos were sorted at 29 hpf, 
based on a slight curvature of the tail prior to full maturation of the phenotype by 48 hpf. As proof-of-principle, 
trichostatin A (TSA) was used as a positive control25 to demonstrate that it was possible to sort the mutants just 
prior to chemical exposure and still successfully suppress the tail curvature phenotype (Fig. 1c). his allowed us 
to expose recessive pkd2 mutants to individual compounds rather than using larger groups of embryos with a 
reduced fraction (25%) of mutant embryos.
Taking this approach, we conducted a chemical screen first using the Spectrum library which contains 
a diverse set of 2000 bioactive compounds including FDA-approved drugs28. Ater initial testing at a concen-
tration of 10 µM, 200 compounds of interest were identiied (see Materials and Methods) and ater 2 further 
retests, 13 compounds remained that signiicantly and reproducibly altered the curvature phenotype: 10 com-
pounds enhanced and 3 repressed the curvature (Fig. 1d). Of interest, 8 of the enhancers clustered into 3 chemical 
classes: steroids, coumarins, and lavonoids. Further details of all the hit compounds identiied can be found in 
Supplementary Information (Table S1).
Ǧpkd ?Ǧ
Ǥ he most potent tail curvature enhancer identiied was 5α-Androstan-3,17-dione (CAS No. 846-46-8, 
henceforth referred to as androstandione). Given that male ADPKD patients develop larger kidneys and develop 
ESRD earlier than female patients3,29,30, we decided to study this compound further and investigate the role of 
androgens more extensively. Surprisingly, androstandione proved to be more potent in this assay than other 
androgens including dihydrotestosterone (DHT), the most potent human androgen31, and 11-ketotestosterone 
(11-KT), the most potent ish androgen32. It enhanced dorsal tail curvature from 2 µM (lowest concentration 
tested) to 30 µM, where all treated embryos had tails that curled well beyond the body axis (Fig. 2a). In com-
parison, DHT and 11-KT only signiicantly altered tail curvature at 50 µM and 30 µM respectively (Fig. S1). 
Norethynodrel, a synthetic progesterone, was also identiied from the screen (Fig. 1d). It is rapidly metabolised 
into α- and 3β-OH-NOR33, neither of which are well characterised. However, oral administration of norethyno-
drel has been associated with progesterone receptor activation as well as weak androgenic activity34. Diferences 
in the chemical structure and potency of the diferent androgens tested in this assay are shown in Fig. 2e.
We next examined the ability of the androgen receptor (AR) antagonist lutamide to inhibit the efect of 
androstandione. As shown, lutamide did not inhibit the tail curvature induced by androstandione nor did it 
have an independent efect (Fig. 2b). hese results raised the possibility that androstandione could be acting via 
an AR-independent pathway.
To prove that this was the case, we took a genetic approach by generating pkd2 mutant ish lacking the ar gene 
by CRISPR/Cas mutagenesis. A CRISPR sequence designed to mutate the ar gene was injected into pkd2/+em-
bryos, G0 carriers were raised and the sh516 allele was isolated. his allele contains a 2 bp deletion (GC) at codon 
453 of the zebraish ar gene, leading to a frameshit and a premature stop ater the addition of 15 novel aa in the 
AR protein. We conirmed that this mutation resulted in loss of secondary sex characteristics (such as anal in col-
our) in males but preservation of the withdrawn external genital papilla (Fig. S2a). Histological sections demon-
strated signiicantly distorted and disorganised testicular structures which lacked large spermatozoa pools in ar 
mutants (Fig. S2b). hese features are consistent with previously reported ar knockout zebraish mutants35–37. 
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pkd2/ + ;ar/ + ish were then bred and the embryos treated with androstandione or vehicle (DMSO) to assess the 
efect on tail curvature. Loss of ar did not alter curvature enhancement by androstandione nor had an independ-
ent efect on the curvature phenotype (Fig. 2c).
A number of rapid, plasma membrane located androgen signalling pathways independent of the AR have 
been identiied over the last decade38. One such pathway is the direct inhibitory action of androgens on L-type 
calcium channels (LTCC)39–43. Of interest, LTCC subunits (Cav1.2) are reported to be expressed in primary cilia, 
zebraish cav1.2 morphants exhibit “cystic kidneys” and lentiviral Cav1.2 knockdown in Pkd1
+/− mice resulted in 
severe PKD44. To further investigate this possibility, we utilized a potent LTCC antagonist (Nifedipine) and ago-
nist (BayK8644) to assess their ability to modify tail curvature in pkd2 embryos. As shown (Fig. 2d), BayK8644 
had no efect on tail curvature while nifedipine only slightly increased tail curvature. However, nifedipine had a 
signiicant efect in counteracting the efect of androstandione although BayK864 was neutral in the same assay 
(Fig. 2d). herefore, although it is possible that androstandione could be acting as an inhibitor of LTCC, this is 
likely to be a minor pathway.
To investigate the role of other non-canonical androgen signaling pathways, we interrogated published 
microarray data of diferential gene expression in cystic and non-cystic cell lines45. here was no diference in 
expression in any of the four LTCC subunits or other potential non-canonical androgen receptors (Fig. S3). 
Further analysis was performed in microarray data derived from normal (non-ADPKD) and ADPKD human 
kidneys, the latter discriminating between minimally cystic tissue (MCT), small, medium and large cysts46 (see 
Materials and Methods). here was signiicantly reduced expression of ZIP9 and the LCC subunit CaV1.2 in all 
cysts from human ADPKD kidneys (Fig. S4).
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Figure 1. A high through-put zebraish screen of pkd2−/− phenotype modulators. (a) Worklow of compound 
screen on pkd2 tail curvature phenotype. (b) pkd2−/− embryo at 3 dpf with schematic indication of curvature 
measurement. 180° - straight tail, 0° - tail crosses body axis. (c) Curvature analysis of pkd2 mutants exposed 
from 27 hpf to DMSO or 200 nM TSA. Example images of curvature next to y-axis. Signiicance via Mann-
Whitney test; ****p ≤ 0.0001. (d) Combined data on hit compounds of the Spectrum library ater initial 
compound screen, validation and cherry-picked compound exposures. Enhancers of pkd2 curvature in red, 
repressors in green. Representative tail curvature images on the let of results. Chemical classes as indicated. 
Mean of DMSO baseline indicated with black line. Signiicances via Kruskal-Wallis test; ****p ≤ 0.0001, 
***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 and non-signiicant (ns): p > 0.05. (a) created using BioRender.com.
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ȋȌǤ Using 
the same strategy, we conducted a second chemical library screen using the Published Kinase Inhibitor Set 
(PKIS) set of 367 kinase inhibitors to identify additional repressor compounds47. 18 consistently active com-
pounds were identiied with the majority enhancing tail curvature as in the Spectrum compound screen (Fig. 3a). 
Because of their potential applicability for drug development, we decided to focus on the four identiied repres-
sor compounds and their respective kinases: GW785804X (PKIS_04), GW780159X (PKIS_59), SB-698596-AC 
(PKIS_96) and GW682841X (PKIS_41).
Conirmatory testing with new batches of chemicals replicated these indings except for PKIS_96 which we 
therefore discarded (Fig. 3b). Glomerular diameter was also assessed using pkd2hu2173/hu2173−/−;wt1b:GFP embryos 
since GFP expression driven by the Wilms tumour 1b (Wt1b) promoter allows visualisation of the pronephros: 
glomerular diameter was unafected by any of the four PKIS repressor compounds (Fig. 3c).
Based on published information, PKIS_04 and PKIS_59 are known to inhibit KDR (kinase insert domain 
receptor)and PKIS_41 inhibits MAP4K4 (mitogen-activated protein kinase kinase kinase kinase 4)48. As shown, 
PKIS_04 and PKIS_59 have a very similar chemical structure (Fig. 3d). In addition, we noted that three PKIS 
repressor compounds were initially designed to inhibit ALK5 (Table S2).
Ǥ Next, we tested the abil-
ity of our chemical hits to modify cyst formation in 3D assays. Two cell lines were used: MDCKII cells49,50 and 
a human-derived PKD1 cystic cell line (OX161c1)45,51. Initial pilot experiments were conducted over a range of 
concentrations to exclude cell toxicity at the doses tested.
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Figure 2. Androgens modulate tail curvature in pkd2−/− embryos independently of AR. (a) Dose-response 
efects of androstandione on tail curvature in pkd2−/− zebraish embryos. (b) Efects on tail curvature in 
pkd2−/− zebraish embryos with co-exposure of androstandione and the anti-androgen lutamide. (c) he efects 
of androstandione on tail curvature in pkd2−/−;ar−/− embryos. (d) Efects of co-exposure of androstandione 
(10 µM) and the LTCC inhibitor, nifedipine (10 µM) or agonist, BayK8644 (30 µM), on tail curvature of pkd2−/− 
zebraish embryos. All results represented by mean +/− SEM. Signiicance via one-way ANOVA with Dunnett’s 
multiple comparisons. P values represented by * (****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 and non-
signiicant (ns): p > 0.05.). (e) Chemical structures of androgens and their potency on pkd2−/− tail curvature 
with androstandione being the most potent and norethynodrel the least potent. Circles are positioned at C3 and 
C17, with the complexity of side groups at these locations correlating with potency of the compound.
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Overall, the results in both cell assays for the Spectrum library compounds showed similar results to those 
predicted from the zebraish screens i.e. enhancers increased cyst area and repressors reduced cyst area, although 
statistical signiicance was not reached for all compounds from two independent replicate experiments due to 
variability (Fig. 4a,b). here were, however, several diferences between the lines: androstandione had a more 
potent efect in OX161c1 than MDCKII but the converse was true for the three repressor compounds: the three 
repressor compounds from the PKIS library had a more pronounced in the MDCKII cells at the concentrations 
tested (Fig. 4c,d). hese could relect cell type or species diferences.
To further assess the eicacy of our identiied repressor compounds, we tested their efects in the presence of 
Forskolin. Forskolin is a known agonist of adenylate cyclase and has potent cystogenic efects. he results were 
consistent between the two cell lines with diclofenac the most potent repressor and zinc pyrithione, the least 
(Fig. S5).
Ƥ ?Ǥ As shown on the heat map (Fig. 5a) of potential kinases targeted by 
PKIS_04, 41 and 59, we identiied Kinase insert domain receptor (KDR) as the most relevant target for PKIS_04 
and _59 whilst MAP4K4 was the most prominent kinase when all three repressors were combined. However, 
other potent inhibitors of KDR (Fig. 5b) and MAP4K4 (Fig. 5c) present in the library on tail curvature had no 
efect on tail curvature, suggesting that neither kinase was likely to be relevant in this assay.
We noted that PKIS_04 and PKIS_59 were initially designed alongside PKIS_41 to inhibit ALK5 (also known 
as TGFßR1 - transforming growth factor, beta receptor I) (Table S2). Although ALK5 was not amongst the orig-
inal kinases tested48 in the initial characterisation of the PKIS compound collection, ALK5 inhibiting properties 
for these compounds have been reported52,53. To conirm that ALK5 was indeed the relevant kinase targeted, we 
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6SCIENTIFIC REPORTS |           (2020) 10:72  | ǣȀȀǤȀ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
www.nature.com/scientificreportswww.nature.com/scientificreports/
tested the efect of a structurally-unrelated ALK5 inhibitor (SD208) with higher speciicity54. As shown, SD208 
had a profound efect in repressing tail curvature in pkd2 embryos at two concentrations (10 and 30 µM) (Fig. 5d).
In MDCK cysts, suppression of cyst growth was observed at even lower concentrations of SD208 (0.1 and 1 
µM) (Fig. 6a). he inhibitory efect of this ALK5 inhibitor was associated with a signiicant suppression of prolif-
erative (Ki67 positive, Fig. 6b) and apoptotic (cleaved caspase-3 positive, Fig. 6c) cell number without an obvious 
efect on lumen formation (podocalyxyn or gp135, Fig. 6d). hese results lead us to conclude that ALK5 activity 
has a stimulatory role in cyst growth.
To conirm our indings, we again interrogated a published microarray of diferential gene expression in nor-
mal (non-ADPKD) and ADPKD human kidneys46. ALK5 expression was signiicantly increased even in MCT 
and cysts whereas ALK4 expression was unchanged in MCT but signiicantly decreased in all cysts (Fig. 6d,e). 
SMAD2 expression was significantly increased in all cysts and SMAD3 expression increased in large cysts 
(Fig. S6).

In this paper, we report the results of the irst unbiased chemical library screen conducted in a zebraish model 
of ADPKD using tail curvature of pkd2−/− embryos as a phenotypic readout. Positive hits (both enhanc-
ers and repressors) were then conirmed in 3D cyst assays using two cell lines, one being a well characterised 
human PKD1 patient-derived cystic cell line. Our approach identiied a number of potent modulators of cyst 
growth including two major signalling pathways: androstandione acting via AR-independent signalling and 
ALK5-mediated signalling.
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he use of tail curvature as a phenotypic readout for the screens has been previously reported in a smaller 
focussed library screen25. To our knowledge however, this is the irst report of a larger unbiased chemical screen 
using a pkd2 zebraish model. We had initially planned to use glomerular dilatation as the primary readout but 
were unable to do so due to the lack of this feature in the mutants and its inconsistency in MO treated ish. he 
absence of pronephric cysts or dilatation in several pkd2 mutant strains has been reported by other groups with-
out a clear explanation19,22,55, although Schottenfeld et al. have reported that maternal RNA could explain this 
observation22. To exclude compensatory efects of maternal pkd2 mRNA in the embryos, we injected low doses 
of an ATG-MO but did not observe pronephric dilatation (Fig. S7). In comparison, pkd1 mutant ish have been 
reported to develop pronephric cysts with full penetrance (100% at 3 dpf for pkd1a/b double knockouts) although 
an earlier paper reported a lower frequency (10–20%) with MO knockdown56,57.
Although the ‘curly-up’ tail phenotype of pkd2 mutants and morphants is consistent and well described, its 
molecular basis is not well understood. he most likely explanation proposed is an increase in extracellular matrix 
deposition due to an increase in the production and/or deposition of collagen IIα257. Early changes in ECM dep-
osition have been observed in the ADPKD kidney and are likely to be a component of the multiple and complex 
mechanisms underlying cystogenesis58,59.
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hree chemical classes could be deined from the compounds identiied from the Spectrum library: steroids, 
coumarins and lavonoids (Table S1). Of interest, the COX-2 inhibitor, diclofenac, was identiied as one of three 
repressors. Preliminary evidence that PGE2 signalling may play a role in ADPKD has been reported especially in 
cellular assays60,61. We were able to conirm the repressor efect of the HDAC inhibitor, TSA, on tail curvature, as 
previously reported25.
Two out of three compounds identiied in the steroid group were androgens. he most potent efect of all 
the enhancers was observed with androstandione and it should be noted that both epiandrosterone and DHT 
can also be converted to androstandione62,63 (Fig. 2e). he much higher potency of androstandione compared 
to DHT or 11-KT as well as the inability of lutamide to block its efect led us to conclude that it was acting 
via a non-canonical androgen signalling pathway. Genetic evidence using a zebraish ar mutant conirmed that 
this was indeed via AR-independent signalling. Potential candidates for this non-canonical pathway include 
GPRC6A64, ZIP965,66, OXER167 and L-type calcium channels (LTCCs)39–43. Testosterone has been shown to bind 
to these receptors, mediating non-genomic activity which is independent of AR (Fig. 7). Of interest, we found a 
curvature enhancing efect of the speciic LCC inhibitor nifedipine39 which also partially ameliorated the efects 
of androstandione, suggestive of LCC competitive antagonism41. Although signiicant, the efects were of a lower 
magnitude compared to that of androstandione suggesting that other AR-independent pathways are likely to be 
involved.
he three kinase repressor compounds identiied from the PKIS screen recognised ALK5 or TGFß receptor-1 
as the common target. We conirmed these indings both positively and negatively by using a more selective and 
structurally unrelated ALK5 inhibitor (SD208) and testing the efect of inhibitors to the other putative kinases 
(MAPK4 and KDR) in the tail curvature assay. Importantly, SD208 also inhibited cyst growth in MDCK cells by 
inhibiting cell proliferation.
here are two branches of the TGFß family: he ALK5 (TGFßR1)/TGFßR2 receptor complex and the ALK4/
activin receptor II b complex - both of which ultimately activate SMAD2/3, transcription factors that are the 
main efectors of the TGFß pathway. It is well known that TGFß signalling mediates a wide range of down-
stream efects including cell proliferation, diferentiation, apoptosis and extracellular matrix deposition (reviewed 
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Figure 6. ALK5 as a modulator of cystic growth in cell culture and expression of ALK4/5 in human ADPKD 
kidneys. Efects of SD208 (1 and 0.1 µM) ater 10 days exposure on cyst area (a), proliferation (b) and 
apoptosis (c) in MDCKII cells compared to DMSO and forskolin controls. Results represented by median 
+/− IQR. Signiicance via Kruskal-Wallis test with Dunn’s multiple comparison, p values represented 
by * (****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 and non-signiicant (ns): p > 0.05.). (di, ii, iii) 
Representative images of SD208 efects on cyst area, proliferation and apoptosis respectively compared to 
DMSO or forskolin. Podocalyxin/gp135 was used to deine lumen formation with nuclear DAPI marker (di), 
Ki67 and cleaved caspase 3 antibodies used to measure proliferation and apoptosis respectively with phalloidin 
apical markers (dii and diii). Microarray expression proile of ALK5 (e) and ALK4 (f) in human kidney tissues 
derived from 5 polycystic kidney samples and 3 non-polycystic kidney samples. Polycystic sample tissues 
are separated into minimally cystic, small cysts (<1 ml), medium cysts (10–20 ml) and large cysts (>50 ml). 
Results represented by mean +/− SEM. Signiicance via one-way ANOVA with Dunnett’s multiple comparison, 
p values represented by * (****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 and non-signiicant (ns): 
p > 0.05).
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in68), all of which have been implicated in ADPKD disease progression69. Both SMAD2 and 3 are upregulated 
in a variety of mouse models and in human tissues even at early ADPKD disease stages where they are associ-
ated with renal ibrosis and epithelial-to-mesenchymal transition (EMT) processes70,71. An overview of the pro-
posed ALK5 dependent pathway in pkd2 mutant zebraish is represented in Fig. 7. Given that SD208 has not 
been reported to inhibit ALK4, it is likely that ALK5 rather than ALK4 is the driver behind the reduction of 
the ADPKD-related phenotype in zebraish. In this context, activation of SMAD2/3 by luid shear stress has 
been demonstrated in immortalised proximal tubular epithelial cells (PTEC) derived from Pkd1lox,lox mice72. his 
response was ALK5-dependent and signiicantly increased in Pkd1−/− PTEC cells, suggesting a role for exagger-
ated ALK5-SMAD2/3 signalling in cystogenesis. ALK5 inhibition has been found to reduce ibrosis and extracel-
lular matrix protein deposition in vitro73. hese observations lend support to our indings that ALK5 inhibition 
can ameliorate the cystic phenotype.
It has been reported that genetic ablation of TGFß-1 in renal epithelial cells of Pkd1 mutant mice had no efect 
of cyst development or on SMAD2/374 implicating ALK4 signalling as the primary driver of TGFβ mediated 
pathology in ADPKD. hese diferences could relate to species, model or stage of disease. In support of this, 
our indings from a published human microarray indicate that ALK5 rather than ALK4 expression is increased 
even in early disease (MCT) with increased SMAD2 expression detectable in small cysts. Of interest, a recent 
meta-analysis of human and mouse PKD arrays is consistent with our indings75.
In conclusion, from a large unbiased chemical library screen in zebraish pkd2 embryos, we have identiied 
AR-independent androgen signalling and ALK5 signalling as potential drivers of disease progression in ADPKD. 
he link with androgens conirms clinical observations of gender-diferences in renal prognosis in ADPKD3,29,30, 
gender dimorphism in non-orthologous PKD rodent models76 and the protective efects of castration or oestro-
gens in males77. he link with ALK5 and TGFβ signalling conirms a large body of literature showing changes in 
ECM in early ADPKD. Both pathways will be the subject of future investigation.

ƤǤ Zebraish were kept under standard conditions (14 h light/10 dark cycle, temper-
ature 26–28 °C78). Rearing occurred in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM MgSO4, 0.33 mM CaCl2 
and methylene blue) and staging according to79. To prevent pigmentation, larvae were treated with PTU (phe-
nylthiourea) beginning from 24 hpf (28 °C) when necessary80. Zebraish lines in this project included, amongst 
others, LWT (London wild type), AB and pkd2hu2173. All procedures adhered to Home Oice legislation.
Figure 7. Model for role of ALK5 and non-canonical androgen signaling in ADPKD. (a) TGFβ binds to 
ALK5 (TGFβ-receptor 1) or ALK4 (not shown) at the plasma membrane to activate the transcription factors 
SMAD2/3. SMAD2/3 in turn activate other TGFβ regulated genes to promote cyst expansion and disease 
progression by efects on inlammation, extracellular matrix accumulation, proliferation and apoptosis. (b) 
Androgens bind to androgen receptors (AR) in the cytoplasm resulting in translocation of the complex to the 
nucleus. he AR-androgen complex modulates gene transcription of androgen related genes in the canonical 
signaling pathway. Androgens can also bind to and inhibit non-genomic receptors such as L-type calcium 
channels, ZIP9, GPRC6A or OXER1 in a non-canonical, AR-independent pathway. Androgen activation of this 
non-canonical pathway promotes cyst expansion and upward tail curvature. Figure created with BioRender.
com.
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High throughput pkd ?ƤǤ A high-throughput chemical screen was conducted 
by exposing pkd2−/− zebraish to two chemical libraries i.e. the Microsource Discovery’s Spectrum library of 2000 
chemicals and the Published Kinase Inhibitor Set of 367 compounds covering 518 known kinases (PKIS, formerly 
GlaxoSmithKline and subsequently transferred to the University of North Carolina). Zebraish embryos were 
exposed in the following manner:
At approximately 24 hpf chorions were removed with pronase (2 mg/ml for 13 minutes), embryos were washed 
briely and transferred back to 28 °C. As the curly tail phenotype does not set in at the same stage in all embryos 
(onset approx. 27–30 hpf), pkd2 mutants were sorted into a separate dish containing screening medium (E3 
medium, 0.75 × PTU and 1% DMSO) as the curvature became apparent. hree embryos were subsequently 
transferred in 150 µl screening medium to each well of a 96-well plate and 100 µl prepared compound solution 
(compounds diluted in screening medium, prepared the day prior and kept at –20 °C) were added to a inal 
concentration of 10 µM. Exposed plates were incubated at 28 °C for 24 hpf before imaging each well with the 
Ash Phenosight system. his is an automated 96-well plate microscope which takes a single brightield and GFP 
luorescent image of each well allowing image acquisition of a whole plate in 10 minutes. Curvature analysis com-
menced using ImageJ sotware with methods previously described57. DMSO exposed controls were eventually 
combined as no signiicant diferences between the majority of experimental days were observed (Fig. S8) and a 
large control group was established.
Initial hits were chosen via a student’s t-test and re-tested in a second round. Additionally, all compounds were 
retested where more than one embryo had died in the previous exposure round. Compounds were either re-tested 
at 10 µM (if it was apparent that one decaying embryo had deprived the others of oxygen needed for development) 
or 0.3 µM if the compound was toxic, ater careful assessment of the images. Final hit compounds were deter-
mined using one-way ANOVA analysis combining all data collected. To ensure the validity of our hit compounds, 
individual groups were compared with DMSO control exposed embryos solely from the same batches (Fig. S9).
Subsequently, hit compounds were re-ordered and re-testing commenced using the same conditions as before, 
also testing a variety of concentrations. Imaging always commenced between 49–52 hpf (curvature is fully devel-
oped by 48 hpf and remains stable). Hit compound sources are listed below in Supplementary Table S1.
Ǥ To visualise the pronephros, pkd2hu2173/hu2173−/−;wt-
1b:GFP embryos and wt1b:GFP-positive siblings were anaesthetised and immobilised in methylcellulose. Wtb1 
codes for Wilms tumour protein WT1b which is expressed in all parts of the developing pronephros from 17hpf81. 
Imaging occurred dorsally and glomerular area or tubular diameter was measured using Image J.
Ǥ DNA extraction from single embryos was necessary to determine the ar genotype. Single 
embryos were dechorionated, placed individually in sterile tubes and 50 µl of embryo digestion bufer (10 mM 
Tris HCl pH 8, 1 mM EDTA, 0.3% Tween20 and 0.3% NP40) was added. he embryos were subsequently heated 
for 10 min to 98 °C ater which 2 µl proteinase K stock solution (25 mg/ml stock) were added. he embryos were 
then kept at 55 °C for 3 h, which was followed by an inactivation step for 10 min at 98 °C. 2 µl supernatant was sub-
sequently used for PCR reactions. Primers used to genotype ar embryos were GACTCTAACGGCCACTACGG, 
ACGTTAGGGTACGGATGACG. The CRISPR recognition sequence used to generate the ar mutant was 
CCGCACGAGCAGTGGTACCC.
For adult zebraish, in clips were used for sequencing. Fin clips were conducted according to Home Oice 
recommendations and clipped materials were transferred directly into 50 µl fresh base solution (1.25 M KOH and 
10 mM EDTA in MilliQ H2O) in a 96-well plate. he removed tissue was then incubated for 30 minutes at 95 °C 
and the plate vortexed for 5 seconds. Subsequently 50 µl neutralisation bufer (2 M Tris HCl in MilliQ H2O) was 
added to each sample and the plate vortexed again for 10 seconds. Lastly, the extract was centrifuged for 2 min at 
maximum speed and 1.5 µl supernatant used per PCR reaction.
PCR. PCR was used to genotype embryos and enable adult zebrafish sequencing. PCRs were conducted 
according to manufacturer’s speciications with 2x ReddyMix by hermo Scientiic/USA, 5x Firepol Master Mix 
by SolisBioDyne/Estonia or Phusion High-Fidelity DNA Polymerase by New England BioLabs/USA. A diag-
nostic digest was performed using the mwol restriction enzyme (NEB) and CutSmart® Bufer (NEB) according 
to manufacturer’s instructions. 4% agarose gels with ethidium bromide staining were used to visualize DNA 
fragments on a transilluminator. PCR puriication prior to sequencing was performed using the MinElute PCR 
Puriication Kit (Qiagen/ Netherlands) or, if unspeciic ampliication had occurred, the MinElute Gel Extraction 
Kit (Qiagen/Netherlands), according to the manufacturer’s manuals.
 ?Ǥ Cells were grown to conluence, washed in PBS and trypsinized before centrifuging for 5 min 
at 1000 rpm and resuspended in small amount of medium (approximately 400 µl). Rat tail collagen (MDCKII) or 
matrigel (OX161c1) were used as the respective 3D matrices to induce cyst formation. Cysts were induced and 
cultured as previously described45,50,51. 5 µM forskolin served as a positive control. Dose response assays were 
performed for toxicity and eicacy in both cystic cell lines, toxicity was assessed by visual inspection with con-
centrations provoking cell death deemed toxic and excluded. he following concentrations were used; 10 µM for 
Pimpinellin, diclofenac and dibutylhydroxyanisole; 1 µM for androstandione; prenyletin; sphondin and trimeth-
oxylavone; 0.1 µM for hexamethylquercetagetin and 0.01 µM for Zinc pyrithione. he medium (with compound) 
was prepared on the day the cells were seeded in a quantity suicing the entire assay. MDCK cells were grown 
at 37° in Gibco DMEM/F-12 medium with 10% FBS, 1% Penicillin/Streptomycin and 1% L-glutamine media 
whee as OX161c1 cells were grown at 33 °C in Gibco DMEM/F-12 medium with 5% Nu-Serum, 1% Penicillin/
Streptomycin and 1% L-glutamine. Medium on the cells was exchanged every 2–3 days and the cysts imaged and 
analysed with ImageJ.
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in situ. To assess apoptosis and proliferation in cystic cell culture, 
immunoluorescence was used with anti-cleaved caspase-3 (Cell Signalling Technologies) or Ki-67 (Dianova) 
primary antibodies. Lumen formation was visualized using an antibody to podocalyxin (gp135) or phalloi-
din. MDCK cells were exposed to compounds of interest for 10 days before rinsing with PBS and digestion for 
10-minutes at 37 °C with 100 U/ml collagenase (Sigma-Aldrich). Cells were then ixed in 4% PFA for 60 min-
utes, quenched with 0.15 mol/l glycine (Sigma-Aldrich) and permeabilized for 60 minutes with 0.1% Triton 
X-100 (VWR). Cells were blocked with 5% BSA for 60 minutes before incubation with primary antibodies to 
Ki-67 or cleaved caspase-3 in 5% BSA for 24 hours at 4 °C. he cells were then washed for an hour four times 
before incubation with the secondary antibody, Alexa Fluor® 488 conjugated-antibody (Life technologies), for 
a further 24 hours at 4 °C. Further 1 hour washes were subsequently performed before a 1-hour incubation with 
4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) at a concentration of 200 ng/ml. Ater washing, cells were 
mounted for microscopy with Vectashield (Vector Laboratories). Imaging was performed using an Olympus 
inverted IX71 microscope and analyzed using ImageJ sotware. he percentage of cysts with more than 5 nuclei 
with cleaved caspase-3 staining and percentage of Ki-67 cells per cyst were used to calculate apoptosis and pro-
liferation rates respectively.
	ƤǤ Adult zebraish were culled and ixed in 4% paraformaldehyde for 3–4 days at room 
temperature. Fixed zebraish were then washed with PBS and decalciied with 0.25 M EDTA at room temperature 
for 2–3 days before being immersed in 70% ethanol. Adult zebraish were then parain embedded and sectioned 
using a microtome.
Ǥ he original human microarray dataset was identiied and downloaded from the 
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) (ID: GSE7869) as raw CEL iles. he array 
was performed using GPL570 (Afymetrix Human Genome U133 Plus 2.0 Array). he kidney samples included 
5 polycystic kidneys and 3 non-cancerous cortical tissue samples from kidneys removed for renal cell carcinoma 
as described by Song et al.46. he 5 polycystic kidney samples were separated into minimally cystic tissue (MCT) 
(n = 5) and small (<1 ml, n = 5), medium (10–20 ml, n = 5) and large cysts (>50 ml, n = 3)46. For cystic cell micro 
array expression analysis, a previous dataset was identiied and downloaded from the ArrayExpress data base 
(https://www.ebi.ac.uk/arrayexpress/) (ID: E-MTAB-4189). he cell culture micro arrays are derived from two 
non-cystic cell cultures and three cystic cell cultures as outlined by Streets et al.45. Individual gene expression 
analysis was performed using Transcriptome Analysis Console (TAC), hermo Fisher Scientiic. Where multiple 
probes targeted the same gene, the sum of probe intensities was used for analysis.

All zebraish were maintained under standard conditions in UK Home Oice–approved aquaria at the Bateson 
center aquaria in the University of Sheield. All procedures adhered to Home Oice legislation and are subject to 
Animal Welfare and Ethical Review Bodies.
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